Achieve Life Sciences (ACHV) Other Non-Current Assets (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Other Non-Current Assets came in at $265000.0 in Q1 2026, down 11.67% YoY from $300000.0 in Q1 2025, and up 409.62% on a QoQ basis from $52000.0 in Q4 2025.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Other Non-Current Assets data on file, last reported at $265000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 11.67% year-over-year to $265000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265000.0 (down 11.67% YoY) and the FY2025 annual result came in at $52000.0, up 33.33% from the prior year.
- Other Non-Current Assets climbed to $265000.0 in Q1 2026, from $52000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $304000.0 in Q3 2024 to a low of $39000.0 in Q4 2024.
- A 5-year average of $145058.8 and a median of $99000.0 in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 310.81% — and 2025, when it plunged 78.62%.
- Tracing ACHV's Other Non-Current Assets over 5 years: stood at $123000.0 in 2022, then decreased by 25.2% to $92000.0 in 2023, then tumbled by 57.61% to $39000.0 in 2024, then jumped by 33.33% to $52000.0 in 2025, then jumped by 409.62% to $265000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $265000.0 (Q1 2026), $52000.0 (Q4 2025), and $65000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Achieve Life Sciences | 369.90 Mn | 369.90 Mn | - | 268,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 268,000.00 |
| Mar 31, 2026 | 265,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Sep 30, 2024 | 304,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Dec 31, 2023 | 92,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2022 | 239,000.00 |
| Jun 30, 2022 | 240,000.00 |
| Mar 31, 2022 | 253,000.00 |
| Dec 31, 2021 | 183,000.00 |
| Sep 30, 2021 | 235,000.00 |